Transthyretin Amyloidosis Treatment Market Size to Reach USD 14.28 Billion by 2031 Amid Rising Adoption of Disease-Modifying Therapies

Introduction

According to Mordor Intelligence, the transthyretin amyloidosis treatment market size is expected to reach USD 7.05 billion in 2026 and is forecast to grow to USD 14.28 billion by 2031, registering a CAGR of 15.17% during the forecast period. Increasing regulatory approvals for disease-modifying therapies and growing awareness of transthyretin amyloidosis are contributing to market expansion across several healthcare systems.

The transthyretin amyloidosis treatment industry is benefiting from improved diagnostic approaches and broader access to specialized therapies. Healthcare providers are identifying more patients through improved screening programs and updated cardiology guidelines that include amyloidosis markers. Pharmaceutical companies are also increasing investments in stabilizers, silencers, and gene-editing therapies aimed at reducing disease progression and improving patient outcomes.